Study of SHR-A1811 for HER2-positive bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have bile duct cancer that is HER2-positive and has spread or is locally advanced.
- You have not had any previous chemotherapy or targeted therapy for advanced bile duct cancer.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your organs (like liver and kidneys) are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This study tests a new drug called SHR-A1811, given by different methods, to find the best way to treat advanced HER2-positive breast cancer. It may help if you have had few treatments so far and have not had this type of drug before.
This trial tests a new drug, SHR-A1811, given alone or followed by a standard treatment, before surgery for early-stage HER2-positive breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
This trial tests a new targeted drug (SHR-A1904) in people with advanced biliary tract cancer whose tumors have a specific protein (Claudin18.2) and who have already tried at least one standard treatment. The goal is to see if this drug can shrink the cancer or slow its growth.
Hear when a new HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.